Latest research on Reyataz

Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once-daily (rather than requiring multiple doses per day) and has lesser effects on the patient's lipid profile (the amounts of cholesterol and other fatty substances in the blood). Like other protease inhibitors, it is used only in combination with other HIV medications. The U.S. Food and Drug Administration (FDA) approved atazanavir on June 20, 2003. [Wikipedia]

Latest findings

The COREYA study (COhort with Reyataz) was a retrospective analysis of a large prospective multicentric cohort of HIV-1-infected subjects in 5 teaching hospitals in France. [source, 2012]
The patient started HAART with Combivir (GlaxoSmithKline, London, UK), Reyataz (Bristol-Myers Squibb, New York, NY, USA), and Norvir (Abbott, Chicago, IL, USA). [source, 2012]
From these facts we have experienced a patient of 68 years, HIV + since 28 years, under active antiretroviral therapy (Epivir, Reyataz, resveratrol) (another presentation at this conference), the following chemotherapy: Epivir (150mg 2daily), resveratrol (500mg 2daily), D-Mannose (1 g 3daily), Omacor (1 g 2daily). [source, 2012]
Reyataz (atazanavir) was obtained from Bristol-Myers Squibb (Princeton, NJ). [source, 2011]
Due to a progressive reduction in CD4+ lymphocytes count, on May 3rd, 2007 the patient started ART consisting of Combivir 1 tablet b.i.d. and Reyataz 400 mg q.d. [source, 2011]
BMS also has Reyataz, an inhibitor that targets HIV protease, on the market, as well as a hepatitis drug, Entecavir, which is a nucleoside inhibitor of the polymerase in hepatitis B. [source, 2010]